Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SQNS - maybe they're announcing the $4 million tax collection today. would be a nice add on to any signed OEM deal or other contract. would definitly get some attention. imo
seems like the new format doesn't affect the ihub app so far. i'm mobile most of the time and i can't see a difference compared to yesterdays format here. charts are fully shown too.
i really do. good luck.
maybe you got mine. sold @$1.84. didn't like the weak trading on an ultrastrong market day like today. GL though.
ETRM - close > $1.47 would be very nice, imo.
Price Target $3.75 by Dawson James
Coverage initiated on ARCA biopharma by Dawson James on 10/09/2013.
http://finance.yahoo.com/q/ud?s=ABIO
one investor is holding 2M shares (18.26% of O/S) and he built his position during the last weeks. nice. also that makes O/S 10.95M shares.
ih.advfn.com/p.php?pid=nmona&article=59514751
maybe it's him:
Mr. Riley Young McCormack is a Co-Founder at Tracer Capital Management L.P. He co-founded the firm in 2004. Prior to this, Mr. McCormack was employed at Coatue Capital.
investing.businessweek.com/research/stocks/private/person.asp?personId=39637057&privcapId=7757258&previousCapId=7757258&previousTitle=Tracer%20Capital%20Management%20L.P.
Agenus (AGEN) Remains Buy at Maxim, Price Target Remains $19
Oktober 8, 2013 9:08
Maxim Group maintained a Buy rating on Agenus Inc. (NASDAQ: AGEN) with a price target of $19.00 (unchanged).
For an analyst ratings summary and ratings history on Agenus Inc. click here. For more ratings news on Agenus Inc. click here.
Shares of Agenus Inc. closed at $2.78 yesterday, with a 52 week range of $2.45-$5.40.
from streetinsider copy&paste. i'm mobile and i am not able to link the app.
220k shares on the bid @$1.63. nice block.
ABIO $1.76 rockin' and rollin' today.
MSTX $0.51 Canaccord Genuity initiated coverage on Mast Therapeutics with a Buy rating and a price target of $3.00 (!!).
long way to go there up to $3.
www.streetinsider.com/New+Coverage/UPDATE%3A+Canaccord+Starts+Mast+Therapeutics+%28MSTX%29+at+Buy+-+Correct/8746289.html
ABIO $1.65 broke through $1.60 and closed near HOD. entered gap zone already. super low float. link back for chart and DD.
you're welcome.
add the ticker and press 'get quote' and refresh using 'get quote'.
after 4-5 times there will come a break with no quotes and a 'skip' button. press 'skip' and you have another 4-6 times to refresh the quotes. then press 'skip' again and so on...
http://www.level2stockquotes.com/level-ii-quotes.html
it's a free one. works for all big stocks. you have to refresh manually, but it works.
thx, i'm mobile - not able to post charts.
ABIO $1.65 with 33k volume. looks like a gapper PM.
ABIO $1.65 with 33k volume. looks like a gapper PM.
$ABIO is fighting to break $1.60 on heavy volume today. if it can manage to break it, there's blue sky ahead.
ABIO $1.57 looks like the run started today. room to fill the gap @$2.70. BOL
ABIO $1.46 had 8x34 cross some days ago. heavy volume the last few trading days with only 16M O/S. MACD, RSI and FullSto look promising and there's a big gap to fill up to $2.30. financing done @$1.60 two months ago, so it looks like heavy accumulation imo.
volume before price.
link back for some DD.
sold today @$4.43. wanted to lock in solid profit. maybe it will fill the gap @~$4.75 but i'm happy. GLTA
SUPN $7.59 and moving on decent volume (~1M shares) after 8x34.
shorts seem to cover now that $7 was broken yesterday.
SUPN $7.63 and moving on decent volume (~1M shares). shorts seem to cover now that $7 was broken yesterday.
SUPN $7.11 with HOD $7.22. looks like break of $7 might finally be done...
SUPN $7.13 maybe the final break today?
broke through big $7 resistance and has now room at least to $10. high short position, two approved drugs already selling.
8x34 cross just happend too.
link back for chart & DD.
i don't think they diluted but of course i don't know it.
as of 06/30/2013 they had cash on hand of roughly $20.3M. they used $1.8M in 6 months from january to june (!!) so i don't think they need cash badly.
also the CEO did buy stock worth $125k @$1.60 so why would he want to dilute now.
looking at the chart imo it looks like heavy accumulation and waiting for the right time and maybe news to pop hard like it did in february.
we need some volume flowing in here. a sudden break through the $7 resistance and i expect SUPN to pop hard. a little spark of news would light it up...
it's only a supplement to the offering that was done back in may.
Prospects Supplement No. 7
(to Prospectus dated May 30, 2013)
Filed pursuant to Rule 424 (b)(4)
Registration No. 333-187508
i had it on my watch list when it was in the $2.20s-2.50s but wanted to wait a little to get closer to the catalysts in Q4. then $heff bought and it spiked. i didn't want to chase and let it go. $heff sold and it went higher again. when PRAN reached $5 i really kicked myself, so i'm glad now to get a second chance down here. maybe it will fill the gap @~$2.50, but i didn't want to jinx it again. will buy significantly more if it closes the gap down there, because i too see a lot of value here.
BOL
bought starter today @$3.51.
will add more if it goes down lower.
$7 is big resistance so far. a break with high volume could possibly spark a short squeeze. there's a gap up to ~$10 too.
SUPN about to breakout. 32% short of float and two approved drugs already selling. nice potential. has consolidated nicely in the $6.50-6.60s the last few weeks.
ABIO worth to take a look. very low O/S (~16M), financing done @$1.60, long consolidation and now gettin' volume - 1.2M shares traded so far.
ABIO also worth to take a look. very low O/S (~16M), financing done @$1.60, long consolidation and now gettin' volume - 1.1M shares traded so far.